In the last trading session, 2.16 million Myriad Genetics, Inc (NASDAQ:MYGN) shares changed hands as the company’s beta touched 1.86. With the company’s per share price at $5.19 changed hands at $0.1 or 1.96% during last session, the market valuation stood at $478.40M. MYGN’s last price was a discount, traded about -464.55% off its 52-week high of $29.30. The share price had its 52-week low at $3.81, which suggests the last value was 26.59% up since then. When we look at Myriad Genetics, Inc’s average trading volume, we note the 10-day average is 2.61 million shares, with the 3-month average coming to 2.09 million.
Analysts gave the Myriad Genetics, Inc (MYGN) stock a consensus recommendation rating of Hold, calculated at a mean rating of 3.12. If we narrow down to specifics, the data shows that 0 out of 7 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 5 recommended MYGN as a Hold, 2 felt it is a Buy and 0 rated the stock as Underweight. Myriad Genetics, Inc’s EPS for the current quarter is expected to be -0.01.
Myriad Genetics, Inc (NASDAQ:MYGN) trade information
Instantly MYGN was in green as seen at the end of in last trading. With action 16.37%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -62.14%, with the 5-day performance at 16.37% in the green. However, in the 30-day time frame, Myriad Genetics, Inc (NASDAQ:MYGN) is 28.78% up. Looking at the short shares, we see there were 7.92 million shares sold at short interest cover period of 2.47 days.
The consensus price target for the stock as assigned by Wall Street analysts is 9.75, meaning bulls need an upside of 46.77% from its current market value. According to analyst projections, MYGN’s forecast low is 6 with 18 as the target high. To hit the forecast high, the stock’s price needs a -246.82% plunge from its current level, while the stock would need to soar -15.61% for it to hit the projected low.
Myriad Genetics, Inc (MYGN) estimates and forecasts
Year-over-year growth is forecast to reach -3.05% down from the last financial year.
Consensus estimates given by 14 financial analysts project the company’s revenue in the current quarter to hit an average of 202.14M. 14 analysts are of the opinion that Myriad Genetics, Inc’s revenue for the current quarter will be 204.53M. The company’s revenue for the corresponding quarters a year ago was 211.5M and 213.3M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -4.43%. The estimates for the next quarter sales put growth at -4.11%.
The 2025 estimates are for Myriad Genetics, Inc earnings to decrease by -106.08%, but the outlook for the next 5-year period is at 24.07% per year.
MYGN Dividends
Myriad Genetics, Inc is expected to release its next quarterly earnings report on 2025-May-05.
Myriad Genetics, Inc (NASDAQ:MYGN)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 2.36% of Myriad Genetics, Inc shares while 104.33% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 106.86%. There are 104.33% institutions holding the Myriad Genetics, Inc stock share, with BLACKROCK INC. the top institutional holder. As of 2024-06-30, the company held 16.7227% of the shares, roughly 15.15 million MYGN shares worth $370.59 million.
VANGUARD GROUP INC holds the second largest percentage of outstanding shares, with 11.1089% or 10.06 million shares worth $246.18 million as of 2024-06-30.
Among Mutual Funds, the top two as of Apr 30, 2025 were iShares Trust-iShares Core S&P Small-Cap ETF and VANGUARD EXPLORER FUND . With 5.5 shares estimated at $28.57 million under it, the former controlled 5.97% of total outstanding shares. On the other hand, VANGUARD EXPLORER FUND held about 3.57% of the shares, roughly 3.29 shares worth around $17.09 million.
